Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation

Published:2014-09-26 Issue:12 Volume:89 Page:E239-E243
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Langerbeins Petra¹,Busch Raymonde²,Anheier Nadine³,Dürig Jan⁴,Bergmann Manuela³,Goebeler Maria-Elisabeth⁵,Hurtz Hans-Jürgen⁶,Stauch Martina B.⁷,Stilgenbauer Stephan⁸,Döhner Hartmut⁸,Fink Anna-Maria¹,Cramer Paula¹,Fischer Kirsten¹,Wendtner Clemens-Martin³,Hallek Michael¹,Eichhorst Barbara¹

Affiliation:

1. Department I of Internal Medicine; Center of Integrated Oncology (CIO), and CECAD-Cluster of Excellence “Cellular Stress Responses in Aging-Associated Diseases,” University of Cologne; Germany

2. Institute of Medical Statistics and Epidemiology, Technical University; Munich Germany

3. Department I of Internal Medicine; Clinical Center Schwabing; Munich Germany

4. Department of Hematology; University Hospital Essen; Germany

5. Department for Internal Medicine II; University Hospital of Würzburg; Germany

6. Hematology/Oncology Group Practice; Halle Germany

7. Private Practice Oncology and Hematology; Kronach Germany

8. Department III of Internal Medicine; University Hospital; Ulm Germany

Publisher

Wiley

Subject

Hematology

Reference28 articles.

1. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group;Fischer;J Clin Oncol,2011

2. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia;Tsimberidou;J Clin Oncol,2008

3. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group;Stilgenbauer;J Clin Oncol,2009

4. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia;Myint;Br J Haematol,1995

5. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia;Eichhorst;Blood,2006

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia;Leukemia & Lymphoma;2024-09-02

2. Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial;The Lancet Oncology;2024-09

3. Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial;Nature Communications;2024-08-09

4. SOHO State of the Art Updates and Next Questions | Contemporary Standard of Care Therapy for Richter's Transformation and Future Directions;Clinical Lymphoma Myeloma and Leukemia;2024-07

5. Molecular Subtypes and the Role of TP53 in Diffuse Large B-Cell Lymphoma and Richter Syndrome;Cancers;2024-06-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3